Background Transforming growth factor beta (TGFβ) cytokines (TGFβ1, TGFβ2, and TGFβ3) play critical roles in tissue fibrosis. [1] However, treating fibrotic diseases with systemic pan-TGFβ inhibitors has demonstrated unacceptable toxicities. [2,3] In human lung liver tissue, the skin of patients sclerosis, elevated TGFB3 gene expression suggests its use as a more specific therapeutic target. [2...